FAQs for NIBIB’s COVID-19 NOSIs

Jump to questions about...


Open All Close All

Emergency Competitive Revisions and Administrative Supplements

Where can I find this Notice?

Who do I contact regarding information about emergency competitive revisions and administrative supplements for COVID-19?

Please contact the NIBIB program officer on your active award.

Who can apply for COVID-19 emergency competitive revision and administrative supplements?

Applicants must hold an active NIBIB grant or cooperative agreement.

Competitive Revisions: Eligible activity codes for emergency competitive revision applications to PA-20-135 are limited to the following mechanisms: DP1, DP2, P41, R00, R01, R03, R15, R21, R24, R37, R41, R43, R44, R56, U01, U18, U24, U2C, U54, UG3, UH2, UH3. 

Administrative Supplements: A list of eligible activity codes for administrative supplements can be found at PA-18-591

What is the difference between a Competitive Revision and an Administrative Supplement?

A Competitive Revision is a request for an increase in support in a current budget period for an expansion of the project’s scope.

An Administrative Supplement provides additional funding to a currently funded grant to meet increased costs that are within the scope of the approved project.

What is a “change in scope?”

A change in scope is a change in the direction, aims, objectives, purposes, or type of research training, identified in the approved project.

Potential indicators of a change in scope include, but are not limited to, the following:

  • Change in the specific aims approved at the time of award.
  • Substitution of one animal model for another.
  • Change from the approved use of live vertebrate animals.
  • Change from the approved involvement of human subjects.

For details please refer to Section 8.1.2.5 of NIH Grants Policy Statement (PDF)

What is award budget is permitted?

Application budgets are limited to no more than the total costs of the currently active budget period of the parent award and must reflect the actual needs of the proposed project.

Will projects in No Cost Extensions be allowed to apply?

NIBIB will allow projects in no cost extension to apply for and obtain funding. The proposed project must be within the currently approved project period for the existing award and not exceed the total costs of the final year of the parent award.

Will paper submission be allowed?

No. Only electronic submissions will be allowed. To avoid delays and processing errors, applications must be submitted the same way that the parent application was submitted. For example, if they originally used ASSIST when submitting, they must use ASSIST to apply to this NOSI. Administrative supplement requests for complex applications must come in electronically as single project applications.

Can PIs be changed or added to these NOSI applications?

No. Do not use the competitive revision application or administrative supplement application to add, delete, or change the PDs/PIs listed on the parent award.

What is the expiration date of this NOSI?

November 10, 2020

What is the funding source for these awards?

Funding will come from the emergency COVID-19 appropriation allocated by congress to NIBIB and may not be used to compensate projects affected by COVID-19. These funds are only applicable to projects related to COVID-19.

Are there addition funding sources available for COVID-19 projects?

Funding may be available through the Point-of-Care Technologies Research Network.

Small Business Research and Development of Biomedical Technologies for COVID-19

Where can I find this Notice?

Who do I contact regarding information about SBIR opportunities related to COVID-19?

Please contact the NIBIB small business program specialists:

Todd Merchak
NIBIB/ESP/OPESP
301-496-8592
NIBIB-SBIR@mail.nih.gov

Ilana Goldberg, PhD
NIBIB/DDST
301-402-3465
NIBIB-SBIR@mail.nih.gov

What is the deadline for submitting a COVID-19 related SBIR application?

April 6th is normal submission date deadline; however, NIH is currently accepting late submissions for this deadline until May 1st with proper justification. See NOT-OD-20-091.

Can Pre-award authority be used for COVID-19 SBIR grants?

Yes, pre-award authority may be used by awardees. Pre-award spending is always done at the recipient’s own risk. As an example, if a grant is issued in August, then under normal policy, the grantee can charge expenses to the grant that occurred within the previous 90 days, (i.e. since May). However, NIH has extended pre-award authority to Jan 20, 2020. See NOT-OD-20-086 allowing reimbursement prior to the standard 90-day period for all recipients affected by COVID-19. Documentation should be provided to the GMS.

Which funding announcements may be used for COVID-19 SBIR grants?

Funding announcements include the current NIBIB SBIR funding mechanisms:

  • PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH Small Business Technology Transfer Grant Applications (Parent STTR [R42/R42] Clinical Trial Not Allowed)
  • PA-19-272 - PHS 201-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-18-631 - NIBIB Exploratory Clinical Trials for Small Businesses ([R44] Clinical Trial Required)

What is the funding source for these awards?

Funding will come from the emergency COVID-19 appropriation allocated by congress to NIBIB and may not be used to compensate projects affected by COVID-19. These funds are only applicable to projects related to COVID-19.

Are there addition funding sources available for COVID-19 projects?

Funding may be available through the Point-of-Care Technologies Research Network

What are the Review Criteria for these awards?

SBIR grants will go through the normal review process and therefore will be reviewed according to the stated review criteria in the FOA. As always, applications will be administratively reviewed for NIBIB mission fit. Applicants are strongly encouraged to contact their Program Director prior to submitting an application.

Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Where can I find this Notice?

Who do I contact regarding information about research project opportunities related to this COVID-19 NOSI?

Send inquiries to COVID19NIBIB@nih.gov

What funding mechanisms are available for new projects associated with COVID-19?

Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents.

  • PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-18-418 - NIBIB Research Project Grant (R01 Clinical Trial Required)
  • PAR-18-530 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
  • PAR-20-155 - Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
  • PAR-20-084 - NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
  • PAR-18-433 - NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)
  • PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  • PA-19-052 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

What is the award budget and project duration?

Responsive Research Project Grants will follow standard process as outlined in the FOA.

What is the expiration date of this NOSI?

March 31, 2021

What is the funding source for these awards?

Funding will come from the emergency COVID-19 appropriation allocated by congress to NIBIB and may not be used to compensate projects affected by COVID-19. These funds are only applicable to projects related to COVID-19.

Are there addition funding sources available for COVID-19 projects?

Funding may be available through the Point-of-Care Technologies Research Network